JP2022041802A5 - - Google Patents

Download PDF

Info

Publication number
JP2022041802A5
JP2022041802A5 JP2020187708A JP2020187708A JP2022041802A5 JP 2022041802 A5 JP2022041802 A5 JP 2022041802A5 JP 2020187708 A JP2020187708 A JP 2020187708A JP 2020187708 A JP2020187708 A JP 2020187708A JP 2022041802 A5 JP2022041802 A5 JP 2022041802A5
Authority
JP
Japan
Prior art keywords
antagonist
weeks
administered
pharmaceutical composition
pruritus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020187708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022041802A (ja
JP7548784B2 (ja
Filing date
Publication date
Priority claimed from JP2020551453A external-priority patent/JP6799831B1/ja
Application filed filed Critical
Priority to JP2020187708A priority Critical patent/JP7548784B2/ja
Publication of JP2022041802A publication Critical patent/JP2022041802A/ja
Publication of JP2022041802A5 publication Critical patent/JP2022041802A5/ja
Application granted granted Critical
Publication of JP7548784B2 publication Critical patent/JP7548784B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020187708A 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物 Active JP7548784B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020187708A JP7548784B2 (ja) 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020551453A JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
PCT/JP2020/032987 WO2022049614A1 (ja) 2020-09-01 2020-09-01 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
JP2020187708A JP7548784B2 (ja) 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020551453A Division JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Publications (3)

Publication Number Publication Date
JP2022041802A JP2022041802A (ja) 2022-03-11
JP2022041802A5 true JP2022041802A5 (enExample) 2023-07-26
JP7548784B2 JP7548784B2 (ja) 2024-09-10

Family

ID=73741045

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551453A Active JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
JP2020187708A Active JP7548784B2 (ja) 2020-09-01 2020-11-11 Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020551453A Active JP6799831B1 (ja) 2020-09-01 2020-09-01 Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物

Country Status (10)

Country Link
US (1) US20230391878A1 (enExample)
EP (1) EP4209227A4 (enExample)
JP (2) JP6799831B1 (enExample)
KR (2) KR102269716B1 (enExample)
CN (1) CN116096411A (enExample)
AU (1) AU2020466800A1 (enExample)
CA (1) CA3189847A1 (enExample)
IL (1) IL300694A (enExample)
MX (1) MX2023002482A (enExample)
WO (1) WO2022049614A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP4062933A4 (en) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
CN120441701A (zh) * 2024-02-07 2025-08-08 武汉人福创新药物研发中心有限公司 一种靶向il-31ra的抗体或其抗原结合片段及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク. 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
JP2002338476A (ja) * 2001-05-21 2002-11-27 Health Factor Kenkyusho:Kk 腎透析に伴う痒みの予防治療剤
EP1576112B1 (en) 2002-01-18 2012-02-29 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
JP2007527712A (ja) 2004-02-12 2007-10-04 レキシコン・ジェネティクス・インコーポレーテッド 新規な遺伝子破壊、これに関する組成物と方法
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
CA2594490A1 (en) 2005-02-14 2006-08-24 Zymogenetics Inc. Methods of treating skin disorders using an il-31ra antagonist
EP1856150A2 (en) 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
KR101446989B1 (ko) 2005-05-06 2014-10-15 지모제넥틱스, 인코포레이티드 Il-31 단클론성 항체 및 사용법
CA2636288C (en) 2006-01-10 2015-02-24 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
CN101589060A (zh) * 2006-01-10 2009-11-25 津莫吉尼蒂克斯公司 使用il-31拮抗剂在神经元性组织中治疗疼痛和炎症的方法
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
RU2009111884A (ru) 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TW201537175A (zh) * 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對il-31拮抗劑之治療的反應之方法
JP6359014B2 (ja) * 2013-08-21 2018-07-18 久光製薬株式会社 貼付剤
US20190135804A1 (en) * 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
WO2019103497A1 (ko) * 2017-11-23 2019-05-31 주식회사 바이로메드 천연추출물을 포함하는 소양증의 예방 또는 치료용 조성물
US20210054085A1 (en) * 2018-04-25 2021-02-25 Kiniksa Pharmaceuticals, Ltd. Treatment of skin diseases or disorders by delivery of anti-osmrb antibody

Similar Documents

Publication Publication Date Title
JP2022041802A5 (enExample)
Kuriyama et al. Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis
TWI738648B (zh) 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
JP2017160178A5 (enExample)
JP2010509369A5 (enExample)
Khan et al. Tramadol use in premature ejaculation: daily versus sporadic treatment
CN111372948A (zh) 用il-17拮抗剂治疗化脓性汗腺炎
JP2020502261A5 (enExample)
JP7309816B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2018515493A5 (enExample)
KR20220112803A (ko) 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US20210386712A1 (en) New use of angiotensin ii type 2 receptor agonist
JP2018534259A5 (enExample)
Aggarwal et al. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study
Saco et al. Prurigo nodularis: Picking the right treatment.
WO2013165590A1 (en) Methods for treating idiopathic pulmonary fibrosis
JP2015522077A5 (enExample)
KR20180017145A (ko) 소양증의 치료
JP2025176134A (ja) 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
KR20230054444A (ko) 호흡기 질환 치료에 사용하기 위한 (1r,3s)-3-((5-시아노-4-페닐티아졸-2-일)카바모일)사이클로펜탄-1-카르복시산 및 이의 유도체
Svecova et al. Clinical manifestation variability of bullous pemphigoid.
AU2015305430A1 (en) Method for treating hyperhidrosis
Lewis et al. Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate
Srinivasu et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen
JPWO2020039256A5 (enExample)